AU2012335009B2 - Calcimimetics and methods for their use - Google Patents

Calcimimetics and methods for their use Download PDF

Info

Publication number
AU2012335009B2
AU2012335009B2 AU2012335009A AU2012335009A AU2012335009B2 AU 2012335009 B2 AU2012335009 B2 AU 2012335009B2 AU 2012335009 A AU2012335009 A AU 2012335009A AU 2012335009 A AU2012335009 A AU 2012335009A AU 2012335009 B2 AU2012335009 B2 AU 2012335009B2
Authority
AU
Australia
Prior art keywords
seq
calcimimetic
pth
dose
arrrar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012335009A
Other languages
English (en)
Other versions
AU2012335009A1 (en
Inventor
Gregory Bell
James E. Tomlinson
Sarah Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47258113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012335009(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of AU2012335009A1 publication Critical patent/AU2012335009A1/en
Application granted granted Critical
Publication of AU2012335009B2 publication Critical patent/AU2012335009B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012335009A 2011-11-10 2012-11-12 Calcimimetics and methods for their use Active AU2012335009B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558389P 2011-11-10 2011-11-10
US61/558,389 2011-11-10
PCT/US2012/064717 WO2013071262A1 (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Publications (2)

Publication Number Publication Date
AU2012335009A1 AU2012335009A1 (en) 2014-05-29
AU2012335009B2 true AU2012335009B2 (en) 2017-08-31

Family

ID=47258113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012335009A Active AU2012335009B2 (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Country Status (9)

Country Link
US (3) US20140315809A1 (https=)
EP (1) EP2776129B2 (https=)
JP (2) JP6204369B2 (https=)
CN (2) CN109985228A (https=)
AU (1) AU2012335009B2 (https=)
CA (1) CA2854911C (https=)
HK (1) HK1202086A1 (https=)
MX (1) MX355063B (https=)
WO (1) WO2013071262A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
MA38724B1 (fr) 2013-06-28 2017-11-30 Amgen Inc Formulation liquide stable d'amg 416 (velcalcétide)
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US20170304286A1 (en) * 2014-10-24 2017-10-26 Launx Biomedical Co., Ltd. New indication of paroxetine pharmaceutical composition for treating cancer
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
US11450405B2 (en) * 2018-10-18 2022-09-20 Fresenius Medical Care Holdings, Inc. Techniques for modeling parathyroid gland functionality and calcimimetic drug activity
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2021115272A1 (zh) * 2019-12-09 2021-06-17 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
EP4212542A4 (en) * 2020-09-10 2024-08-28 Shaanxi Micot Technology Co., Ltd. BISPECIFIC FUSION POLYPEPTIDE COMPOUND
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
EP4353248A4 (en) * 2021-06-08 2024-10-23 Beijing Tuo Jie Biopharmaceutical Co. Ltd. CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF
WO2022257940A1 (zh) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028394A1 (en) * 2009-07-29 2011-02-03 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP4142743B2 (ja) * 1996-07-31 2008-09-03 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモンに関連する新規ペプチド類似体
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
AU7895601A (en) 2000-07-18 2002-01-30 Bone Care Int Inc Stabilized 1alpha-hydroxy vitamin d
WO2003013543A1 (en) * 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
AU2006227429A1 (en) * 2005-03-17 2006-09-28 Amgen Inc. Methods of decreasing calcification
JP5645408B2 (ja) 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
CA2701638A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals Inc. Pharmaceutical calcimimetics
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028394A1 (en) * 2009-07-29 2011-02-03 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOUQIYYEH M.Z. et al., "Survey of Attitudes of Physicians toward the Current Evaluation and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)", Saudi J. Kidney. Dis. Transpl., 2010, Vol. 21, No. 1, pages 93-101 *
SVARA F., "Chronic kidney disease - mineral and bone disorder (CKD-MBD): a new term for a complex approach", Journal of Renal Care, 2009, Vol. 35, Supplement 1, pages 3-6 *

Also Published As

Publication number Publication date
US20140315809A1 (en) 2014-10-23
MX2014005662A (es) 2014-11-10
CN104168955A (zh) 2014-11-26
CA2854911C (en) 2019-09-24
EP2776129A1 (en) 2014-09-17
JP2015502346A (ja) 2015-01-22
JP2017160269A (ja) 2017-09-14
HK1202086A1 (en) 2015-09-18
AU2012335009A1 (en) 2014-05-29
JP6204369B2 (ja) 2017-09-27
EP2776129B2 (en) 2020-06-17
US20170252397A1 (en) 2017-09-07
EP2776129B1 (en) 2017-03-29
MX355063B (es) 2018-04-04
CA2854911A1 (en) 2013-05-16
US20160175383A1 (en) 2016-06-23
CN109985228A (zh) 2019-07-09
WO2013071262A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
AU2012335009B2 (en) Calcimimetics and methods for their use
US20250163103A1 (en) Therapeutic agents for reducing parathyroid hormone levels
HK1241270A1 (en) Therapeutic agents for reducing parathyroid hormone levels
HK1241270B (en) Therapeutic agents for reducing parathyroid hormone levels
HK1167108B (en) Therapeutic agents for reducing parathyroid hormone levels

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)